Journals / Cerrahpaşa Tıp Dergisi / 2009 / Cilt: 40 Sayı: 1

Kanser Kök Hücresi ve Notch Yolağında Umut Veren Ortak Embriyonik Dönem İnhibisyonu

Pages
23–27
Publication Date
2014-07-20
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
🔖

Cite This Article

ÖKTEM, G., USLU, S., UYSAL, A., BİLİR, A., AYLA, Ş., SONER, B., ÇAL, Ç. (2014). Kanser Kök Hücresi ve Notch Yolağında Umut Veren Ortak Embriyonik Dönem İnhibisyonu. Cerrahpaşa Tıp Dergisi, Cilt: 40 Sayı: 1, 23–27. https://ajindex.com/articles/983999

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Strizzi L, Postovit LM, Margaryan NV, et al. Emerging roles of nodal and Cripto-1: from embryogenesis to breast cancer progression. Breast Dis 2008; 29: 91- 103
  2. Leong KG, Gao WQ. The Notch pathway in prostate development and cancer. Differentiation 2008; 76: 699-716
  3. Raaijmakers MH, Scadden DT. Divided within: heterogeneity within adult stem cell pools. Cell 2008; 135: 1006-1008
  4. Dick JE. Stem cell concepts renew cancer research. Blood 2008; 112: 4793-4807
  5. Pearce DJ, Ridler CM, Simpson C, Bonnet D. Multiparameter analysis of murine bone marrow side population cells. Blood 2004; 103: 2541-2546
  6. Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct "side population" of cells in human tumor cells: implications for tumor biology and therapy. Cell Cycle 2005; 4: 203-205
  7. Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004; 101: 14228-14233
  8. Patrawala L, Calhoun T, Schneider-Broussard R, et al. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 2005; 65: 6207-6219
  9. Chen J, Crabbe A, Duppen VV, Vankelecom H The notch signaling system is present in the postnatal pituitary: marked expression and regulatory activity in the newly discovered side population. Mol Endocrinol 2006; 20: 3293-3307
  10. Bozkurt KM. Kemoterapi ve Kanser Kök Hücreleri. ‹stanbul: Uyum Yay›nc›l›k; 2007
  11. Marotta LL, Polyak K. Cancer stem cells: a model in the making. Curr Opin Genet Dev 2009; 19: 44-50
  12. Morrow M, Wait RB, Rosenthal RA, Gamelli RL. Verapamil enhances antitunor activity without increasing myeloid toxicity. Surgery 1987; 101: 63-68. 13. fienel F. Klonlamada yeni ufuklar: Kök hücreler. TÜB‹TAK Bilim ve Teknik Dergisi 2002; (410): 44
  13. Cheng XY, O’Neill HC. Oncogenesis and cancer stem cells: Current opinions and future directions. J Cell Mol Med 2009; 16
  14. Ward RJ, Dirks PB. Cancer stem cells: at the headwaters of tumor development. Annu Rev Pathol 2007; 2: 175-189
  15. Szakács G, Jakab K, Antal F, Sarkadi B. Diagnostics of multidrug resistance in cancer. Pathol Oncol Res 1998; 4: 251-257
  16. Licht T, Fiebig HH, Bross KJ, Herrmann F, Berger DP, Shoemaker R, Mertelsmann R. Induction of multipledrug resistance during anti- neoplastic chemotherapy in vitro. Int J Cancer 1991; 49: 630-637 18. BJ, Osborne BA, Miele L. Notch signaling as a th